Takeda announced that Dexilant, formerly known as Kapidex, (dexlansoprazole) delayed release capsules are now available in United States (U.S.) pharmacies. The decision to rename Kapidex to Dexilant is based on reports of dispensing errors between Kapidex and Casodex (bicalutamide tablets, from AstraZeneca). Both the FDA and Takeda have determined a name change would be the best way to minimize future medication errors. The formulation, indication, and approved dosages of Dexilant will remain the same as Kapidex. Markings on the capsules and the capsule appearance will be identical to capsules marketed under the Kapidex trade name.
Dexilant is indicated for the treatment of erosive esophagitis (EE) and heartburn related to non- erosive gastroesophageal reflux disease (GERD) as well as the maintenance of healing of EE.
For more information call (877) TAKEDA-7 or visit www.tpna.com.